HK1209761A1 - Polypeptides - Google Patents

Polypeptides

Info

Publication number
HK1209761A1
HK1209761A1 HK15110388.2A HK15110388A HK1209761A1 HK 1209761 A1 HK1209761 A1 HK 1209761A1 HK 15110388 A HK15110388 A HK 15110388A HK 1209761 A1 HK1209761 A1 HK 1209761A1
Authority
HK
Hong Kong
Prior art keywords
polypeptides
Prior art date
Application number
HK15110388.2A
Other languages
English (en)
Chinese (zh)
Inventor
Lars Abrahmsn
Caroline Ekblad
Original Assignee
Affibody Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affibody Ab filed Critical Affibody Ab
Publication of HK1209761A1 publication Critical patent/HK1209761A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/081—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK15110388.2A 2010-07-09 2013-08-23 Polypeptides HK1209761A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39928510P 2010-07-09 2010-07-09
US40356110P 2010-09-17 2010-09-17

Publications (1)

Publication Number Publication Date
HK1209761A1 true HK1209761A1 (en) 2016-04-08

Family

ID=44630120

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15110388.2A HK1209761A1 (en) 2010-07-09 2013-08-23 Polypeptides
HK13109912.1A HK1182719A1 (en) 2010-07-09 2013-08-23 Polypeptides

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK13109912.1A HK1182719A1 (en) 2010-07-09 2013-08-23 Polypeptides

Country Status (22)

Country Link
US (3) US9211344B2 (fr)
EP (2) EP2933262B1 (fr)
JP (2) JP5827994B2 (fr)
KR (1) KR101884654B1 (fr)
CN (3) CN110437321A (fr)
AU (1) AU2011275766B2 (fr)
BR (1) BR112013000452A2 (fr)
CA (1) CA2804002C (fr)
DK (2) DK2933262T3 (fr)
ES (2) ES2540114T3 (fr)
HK (2) HK1209761A1 (fr)
IL (1) IL223989B (fr)
LT (1) LT2933262T (fr)
MX (1) MX2013000314A (fr)
MY (1) MY161679A (fr)
NO (1) NO2933262T3 (fr)
NZ (1) NZ604805A (fr)
PL (2) PL2590993T3 (fr)
RU (1) RU2577964C2 (fr)
TR (1) TR201809437T4 (fr)
WO (1) WO2012004384A2 (fr)
ZA (1) ZA201300994B (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120165650A1 (en) * 2010-12-22 2012-06-28 General Electric Company Her2 binders
ES2540114T3 (es) * 2010-07-09 2015-07-08 Affibody Ab Polipéptidos
BR122021020041B1 (pt) 2010-09-28 2023-03-07 Amylin Pharmaceuticals, Llc Polipeptídeo quimérico, seu uso e composição que o compreende
SG195073A1 (en) 2011-05-21 2013-12-30 Macrogenics Inc Deimmunized serum-binding domains and their use for extending serum half-life
JP6006309B2 (ja) 2011-07-08 2016-10-12 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニーＡｍｙｌｉｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｌｌｃ 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
US20140256621A1 (en) * 2011-07-08 2014-09-11 Astrazeneca Pharmaceuticals Lp Engineered poypeptides having enhanced duration of action and reduced immunogenicity
KR102336895B1 (ko) 2012-02-20 2021-12-08 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) 인간 보체 c5에 결합하는 폴리펩티드
KR20140142298A (ko) * 2012-03-28 2014-12-11 애피바디 에이비 경구투여
JP2020033372A (ja) * 2012-03-28 2020-03-05 アフィボディ・アーベー 経口投与
JP6590695B2 (ja) * 2012-09-25 2019-10-16 アフィボディ・アーベー アルブミン結合ポリペプチド
US9745350B2 (en) 2012-10-05 2017-08-29 Affibody Ab HER3 binding polypeptides
EP2912054B1 (fr) 2012-10-25 2017-06-21 Affibody AB Polypeptide se liant a l'albumine
ES2674983T3 (es) 2012-10-25 2018-07-05 Affibody Ab Método para la separación de proteínas que contienen un dominio que se une a albúmina
WO2014076177A1 (fr) * 2012-11-14 2014-05-22 Affibody Ab Nouveau polypeptide
WO2014076179A1 (fr) 2012-11-14 2014-05-22 Affibody Ab Nouveau polypeptide
EP2935335B1 (fr) * 2012-12-19 2020-10-28 Affibody AB Nouveaux polypeptides
MX2015012420A (es) 2013-03-14 2016-06-02 Daiichi Sankyo Co Ltd Nuevas proteinas de union para pcsk9.
US9975943B2 (en) * 2013-03-15 2018-05-22 Affibody Ab Polypeptides
RU2679889C2 (ru) 2013-04-18 2019-02-14 Армо Байосайенсиз, Инк. Способы применения интерлейкина-10 для лечения заболеваний и расстройств
CA2914837A1 (fr) 2013-06-17 2014-12-24 Armo Biosciences, Inc. Methode d'evaluation de l'identite et de la stabilite d'une proteine
CN117964710A (zh) 2013-08-28 2024-05-03 阿菲博迪公司 具有突变的支架的结合多肽
PL3038633T3 (pl) 2013-08-28 2021-07-19 Ipc Research, Llc Stabilne polipeptydy wiążące się z ludzkim dopełniaczem c5
AU2014311432A1 (en) 2013-08-30 2016-03-03 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
JP6660297B2 (ja) 2013-11-11 2020-03-11 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害を処置するためのインターロイキン−１０の使用方法
EP3083675B1 (fr) * 2013-12-20 2018-03-07 Affibody AB Polypeptide de liaison à l'albumine modifié
MX2016015235A (es) 2014-05-22 2017-06-29 Pieris Pharmaceuticals Gmbh Nuevos polipeptidos de union especifica y usos de los mismos.
CN106573072A (zh) 2014-06-02 2017-04-19 阿尔莫生物科技股份有限公司 降低血清胆固醇的方法
AU2015323860B2 (en) 2014-09-29 2021-05-27 Duke University Bispecific molecules comprising an HIV-1 envelope targeting arm
EP3206713A4 (fr) 2014-10-14 2018-06-27 Armo Biosciences, Inc. Compositions d'interleukine-15 et leurs utilisations
MX2017004983A (es) 2014-10-22 2017-11-13 Armo Biosciences Inc Metodos para usar interleucina 10 para tratar enfermedades y trastornos.
PT3245224T (pt) 2015-01-12 2020-10-08 Affibody Ab Polipéptidos de ligação a il-17a
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
EP4272838A3 (fr) * 2015-04-02 2024-01-10 Molecular Partners AG Domaines de répétition d'ankyrine artificiels ayant une spécificité de liaison pour l'albumine sérique
WO2016191587A1 (fr) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Interleukine 10 pégylée utilisée pour le traitement du cancer
AU2016312510A1 (en) 2015-08-25 2018-03-08 Armo Biosciences, Inc. Methods of using Interleukin-10 for treating diseases and disorders
CN111164104A (zh) 2017-08-09 2020-05-15 麻省理工学院 白蛋白结合肽缀合物及其方法
CN108362873B (zh) * 2018-02-13 2021-06-01 苏州仁端生物医药科技有限公司 一种镉离子检测试剂盒及其应用
US11505576B2 (en) * 2018-03-13 2022-11-22 Affibody Ab Polypeptides based on a scaffold
CA3150442A1 (fr) 2019-09-02 2021-03-11 Biotest Ag Proteine du facteur viii a demi-vie accrue
EP3785726A1 (fr) 2019-09-02 2021-03-03 Biotest AG Protéine de facteur viii à demi-vie prolongée
US20220389066A1 (en) 2019-11-05 2022-12-08 Affibody Ab Polypeptides
US20230190881A1 (en) 2020-02-17 2023-06-22 Biotest Ag Subcutaneous administration of factor viii
EP3878515A1 (fr) 2020-03-09 2021-09-15 Hober Biotech AB Agent thérapeutique ciblant her2
CA3200702A1 (fr) 2020-12-21 2022-06-30 Affibody Ab Nouveau polypeptide
US20240124533A1 (en) 2021-02-15 2024-04-18 Affibody Ab New her2-binding polypeptide
CN113416683B (zh) * 2021-06-01 2023-05-02 南昌大学 一种大肠杆菌Nissle 1917基因工程菌及其制备方法和应用
WO2023152144A1 (fr) 2022-02-08 2023-08-17 Affibody Ab Variants de protéine z se liant à la lymphopoïétine stromale thymique et leur utilisation médicale

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US6362225B1 (en) 1999-01-21 2002-03-26 George Andreakos Target therapies for treating common viral infections
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
ATE337403T1 (de) 1999-12-24 2006-09-15 Genentech Inc Verfahren und verbindungen zur verlängerung der halbwertzeiten bei der ausscheidung von biowirksamen verbindungen
US7288265B1 (en) 2000-10-16 2007-10-30 Lectec Corporation Treating viral infection at smallpox vaccination site
IL156690A0 (en) * 2000-12-29 2004-01-04 Savient Pharmaceuticals Inc Specific human antibodies for selective cancer therapy
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2005000222A2 (fr) 2003-05-30 2005-01-06 Amylin Pharmaceuticals, Inc. Nouveaux procedes et nouvelles compositions pour une administration amelioree par voie muqueuse de peptides et de proteines
JP5634008B2 (ja) * 2004-04-06 2014-12-03 アフィボディ・アーベー 新規の使用および方法
US20050282756A1 (en) 2004-06-18 2005-12-22 Mehta Nozer M Oral delivery of peptide pharmaceutical compositions
EP1841796A2 (fr) * 2004-12-02 2007-10-10 Domantis Limited Anticorps bispecifiques de domaine visant l'albumine serique et glp-1 ou pyy
US8093207B2 (en) 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
CN101495515A (zh) * 2006-05-24 2009-07-29 拜耳先灵医药股份有限公司 免疫原性降低的高亲和力人及人源化抗α5β1整联蛋白功能阻断性抗体
AU2007284801A1 (en) 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
EP2069402A2 (fr) * 2006-09-08 2009-06-17 Ablynx N.V. Protéines à demi-vie longue se liant à l'albumine sérique
WO2008043821A1 (fr) 2006-10-11 2008-04-17 Ablynx N. V. Séquences d'acides aminés se liant à des protéines sériques essentiellement indépendamment du ph, composés les comprenant et utilisations correspondantes
EP2190863B1 (fr) * 2007-07-31 2015-09-02 Affibody AB Nouvelles compositions, nouveaux procédés et nouvelles utilisations
EP2077272A1 (fr) 2007-12-21 2009-07-08 Affibody AB Librairies de polypeptides avec une structure d'échafaudage prédéterminée
US10058593B2 (en) 2008-03-26 2018-08-28 Oramed Ltd. Methods and compositions for oral administration of proteins
CN101294178A (zh) 2008-05-26 2008-10-29 江南大学 一种用两阶段培养法提高发酵生产透明质酸产量的方法
CN101294187B (zh) * 2008-06-06 2013-07-31 暨南大学 一种缓释生物活性多肽的方法与应用
RU2494755C2 (ru) 2008-08-18 2013-10-10 Интера Био Лтд. Способы и композиции для перорального введения белков
WO2010054699A1 (fr) * 2008-11-17 2010-05-20 Affibody Ab Conjugués de domaine de liaison d’albumine
EP2437767B1 (fr) 2009-06-01 2015-07-08 MedImmune, LLC Molécules ayant une demi-vie prolongée et leurs utilisations
ES2540114T3 (es) * 2010-07-09 2015-07-08 Affibody Ab Polipéptidos
WO2012016043A2 (fr) 2010-07-29 2012-02-02 The Regents Of The University Of Michigan Analyseur d'impédance multicanal portable sans fil
BR122021020041B1 (pt) 2010-09-28 2023-03-07 Amylin Pharmaceuticals, Llc Polipeptídeo quimérico, seu uso e composição que o compreende
EP2670418A4 (fr) 2011-02-04 2015-06-17 Aegis Therapeutics Llc Compositions de médicament peptidique biodisponible par voie orale et procédés associés
US20140256621A1 (en) 2011-07-08 2014-09-11 Astrazeneca Pharmaceuticals Lp Engineered poypeptides having enhanced duration of action and reduced immunogenicity
KR20140142298A (ko) 2012-03-28 2014-12-11 애피바디 에이비 경구투여
JP6590695B2 (ja) 2012-09-25 2019-10-16 アフィボディ・アーベー アルブミン結合ポリペプチド
EP3083675B1 (fr) 2013-12-20 2018-03-07 Affibody AB Polypeptide de liaison à l'albumine modifié

Also Published As

Publication number Publication date
CN110437320A (zh) 2019-11-12
EP2590993B1 (fr) 2015-05-06
CA2804002C (fr) 2021-07-20
KR101884654B1 (ko) 2018-08-02
US20140162956A1 (en) 2014-06-12
MX2013000314A (es) 2013-01-29
EP2933262B1 (fr) 2018-05-02
JP2013534421A (ja) 2013-09-05
CN103003296A (zh) 2013-03-27
ES2540114T3 (es) 2015-07-08
EP2590993A2 (fr) 2013-05-15
NO2933262T3 (fr) 2018-09-29
PL2590993T3 (pl) 2015-10-30
TR201809437T4 (tr) 2018-07-23
BR112013000452A2 (pt) 2020-02-11
JP6486810B2 (ja) 2019-03-20
DK2933262T3 (en) 2018-06-25
US9211344B2 (en) 2015-12-15
ES2676403T3 (es) 2018-07-19
RU2013102953A (ru) 2014-08-20
HK1182719A1 (en) 2013-12-06
RU2577964C2 (ru) 2016-03-20
WO2012004384A3 (fr) 2012-03-29
IL223989B (en) 2018-10-31
PL2933262T3 (pl) 2018-10-31
CA2804002A1 (fr) 2012-01-12
MY161679A (en) 2017-05-15
AU2011275766B2 (en) 2015-10-22
CN110437320B (zh) 2023-10-20
CN110437321A (zh) 2019-11-12
LT2933262T (lt) 2018-07-10
ZA201300994B (en) 2020-05-27
NZ604805A (en) 2014-09-26
US20160108095A1 (en) 2016-04-21
DK2590993T3 (en) 2015-06-29
EP2933262A1 (fr) 2015-10-21
US10329331B2 (en) 2019-06-25
WO2012004384A2 (fr) 2012-01-12
US20190375799A1 (en) 2019-12-12
JP5827994B2 (ja) 2015-12-02
AU2011275766A1 (en) 2013-01-10
JP2016053047A (ja) 2016-04-14
KR20130034043A (ko) 2013-04-04

Similar Documents

Publication Publication Date Title
HRP20191852T8 (hr) Polipeptidi
HK1209761A1 (en) Polypeptides
DK3342786T3 (en) Anti-dll3-antistof
ZA201309174B (en) Polypeptides
IL222301A0 (en) Protease-activatable pore-forming polypeptides
AP3107A (en) 5-Alkynyl-pyrimidines
EP2566479A4 (fr) Aza-indazoles
EP2640189A4 (fr) 3-deutéro-pomalidomide
DK3466977T3 (en) Anti-vla-4-antistoffer
GB201012651D0 (en) Peptides
EP2651505A4 (fr) Électrosensibilisation induite par électroporation
EP2641891A4 (fr) Activateur de pkc-
GB201016494D0 (en) Polypeptide
GB201018480D0 (en) Factors
EP2627674A4 (fr) Peptides basés sur l'egfr
AU4536P (en) TB01 Tibouchina urvilleana
AU4937P (en) FlatinsulGL Myoporum insulare
AU4932P (en) FlatwaxpinkGL Chamelaucium uncinatum
AU4822P (en) FlatwaxwhiteGL Chamelaucium uncinatum
AU4931P (en) FlatwaxDarkGL Chamelaucium uncinatum
PT2718316T (pt) Polipeptídeos
GB201003906D0 (en) Binding polypeptides
AU2010278V (en) Little Tuffy Lomandra confertifolia
GB201008108D0 (en) Helisuacer III
GB201005840D0 (en) Multi-catch pro